It’s not a cure for Clostridiodies difficile, but it’s certainly a huge step toward finding one for the deadly infection that claims 15,000 lives a year in the United States alone, according to investigators who say they have identified the toxin that the most virulent strains of C. diff releases.
It’s not a cure for Clostridiodies difficile, but it’s certainly a huge step toward finding one for the deadly infection that claims 15,000 lives a year in the United States alone, according to investigators who say they have identified the toxin that the most virulent strains of C. diff releases.
Investigators with CUNY’s Structural Biology Initiative pulled out all the stops in tracking down CDTb, the toxin released by the most dangerous strains of C. diff. The research team, whose findings were published in PNAS, used cryogenic electron microscopy, X-ray crystallography, nuclear magnetic resonance, and small angle X-ray scattering to determine that CDTb needs 2 components to function, making it a binary toxin.
Its lethality mimics anthrax in the way it enters cells, first binding to them and then creating a pore-forming channel that allows CDTb to get in and wreak havoc. Unlike anthrax, CDTb “does not require a lipid bilayer or presence of detergents to form.”
Amédée de Georges, the study’s principal investigator, said in a press release that investigators were “able to combine several increasingly popular biophysical imaging techniques to visualize and characterize every atom of this binary toxin and show us where they are positioned. These details provide a critical and extremely useful starting point for designing drugs that can prevent C. diff infection.”
They also discovered a novel calcium binding site on one of CDTb’s domain, which suggests that calcium plays a crucial part in allowing C. diff to infect cells.
Taken together, the investigators say that “the structures of active CDTb will contribute next to answering important new questions regarding the molecular mechanisms of the C. difficile toxin, which can also benefit drug discovery.
Xingjian Xu, a CUNY PhD student and an investigator in de Georges' lab, explained that the research team “observed 2 similar but distinct forms of the C. diff toxin-1 where we see the pore-forming channel and 1 where it is invisible. This gives us clues as to how to prevent the formation of the channel and stop the bacteria from entering the cell.”
This research was funded by the National Institutes of Health, National Science Foundation Division of Chemistry, and the US Department of Health and Human Services.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Telemedicine's Transformative Role in PPE Distribution and Sterile Equipment Management
July 22nd 2025In an era defined by digital transformation and post-pandemic urgency, telemedicine has evolved beyond virtual visits to become a vital infrastructure for delivering personal protective equipment (PPE) and managing sterile supplies. By enabling real-time forecasting, remote quality control, and equitable distribution, telemedicine is revolutionizing how health care systems protect both patients and providers.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.